Anthem Biosciences, a CRDMO, is set to launch an IPO to raise ₹3,395 crore, diluting the promoter group’s stake. While revenue and profit have increased, the company faces geographical and client concentration risks. Despite a high P/E ratio compared to peers, investors with a high-risk tolerance may find the IPO appealing.